Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Ligand | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Ligand

Revenues up 56% in the quarter driven by Captisol

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand

4Q Revenues: $23.0 million (+56%)

4Q Earnings: $7.1 million (+278%)

FY Revenues: $64.5 million (+32%)

FY Earnings: $12.0 million (+5%)

Comments: Royalty revenues increased 32% in the quarter to $9.4 million primarily due to higher royalties from Promaca and Kyprolis. Material sales increased to $13.0 million from $6.8 million in 4Q13 due to higher demand for Captisol for both clinical and commercial uses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters